Allergic Rhinitis Drugs Market Report 2024

The allergic rhinitis drugs market size has grown steadily in recent years. It will grow from $14.99 billion in 2023 to $15.67 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth during the historic period can be attributed to rising awareness about allergic reactions and treatment options, an increasing prevalence of allergic rhinitis, heightened demand for effective medications, and the growing popularity of over-the-counter (OTC) allergy treatments.

The allergic rhinitis drugs market size is expected to see steady growth in the next few years. It will grow to $18.78 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to rising pollution levels and an increase in respiratory disorders, growing environmental pollution, changing climatic conditions, a higher number of individuals suffering from allergies, and increasing awareness about allergic reactions and available treatments. Major trends during this period include technological advancements in treatment methods, the development of new antihistamines, innovations in allergy rhinitis diagnostics, progress in allergy treatment, and increased research and development of new therapies.

The increasing incidence of respiratory disorders is expected to drive the growth of the allergic rhinitis drug market. Respiratory disorders include a variety of conditions that impact the lungs and airways. This rise is largely attributed to greater exposure to environmental pollutants, such as air pollution and allergens, along with climate change and a higher prevalence of respiratory infections. Allergic rhinitis drugs are crucial for managing these disorders, as they reduce inflammation and alleviate symptoms such as nasal congestion and sneezing, thus improving respiratory function. For example, in April 2024, the Centers for Disease Control and Prevention, a US-based governmental body, reported that the percentage of adults with current asthma increased from 8% in 2021 to 8.9% in 2023. Consequently, the growing prevalence of respiratory disorders is fueling the growth of the allergic rhinitis drug market.

Leading companies in the allergic rhinitis drug market are concentrating on innovative treatment methods, such as novel fixed-dose combinations, to stay competitive. These treatments combine several active ingredients into a single, pre-measured dose, aiming to enhance efficacy, simplify administration, and improve patient adherence. For instance, in May 2021, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical firm, introduced the Ryaltris-AZ Nasal Spray. This fixed-dose combination includes Mometasone Furoate 50 mcg and Azelastine 140 mcg and is designed to treat moderate to severe allergic rhinitis in India. The nasal spray delivers higher drug concentrations directly to the site of inflammation, potentially reducing systemic side effects compared to oral treatments.

In January 2022, Glenmark Pharmaceuticals Limited formed a partnership with Lotus Pharmaceutical Co. Ltd. to extend the market reach of Ryaltris into Singapore, Hong Kong, and Vietnam. This collaboration allows Glenmark to utilize Lotus's established network in Southeast Asia for the introduction of Ryaltris, while Lotus will manage commercialization, pending regulatory approvals to ensure compliance and facilitate market entry. Lotus Pharmaceutical Co. Ltd. is a Taiwan-based pharmaceutical company.

Major companies operating in the allergic rhinitis drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceuticals Industries Ltd., Perrigo Company plc, Dr. Reddy’s Laboratories, Apotex Inc., Meda AB, Amneal Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd, ALK-Abelló A/S, Stallergenes Greer plc, Himalaya Wellness Company, Unichem Laboratories Limited, Aytu BioPharma Inc., Allergy Therapeutics PLC, DMK Pharmaceuticals Corporation, Revolo Biotherapeutics.

Asia-Pacific was the largest region in the allergic rhinitis drugs market in 2023. The regions covered in the allergic rhinitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allergic rhinitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Allergic rhinitis drugs are medications used to alleviate symptoms of allergic rhinitis, a condition marked by inflammation of the nasal passages due to allergens such as pollen, dust, mold, or animal dander. These drugs help relieve symptoms such as sneezing, itching, nasal congestion, and a runny nose.

The main types of allergic rhinitis covered by these drugs include seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis. Seasonal allergic rhinitis, often referred to as hay fever, occurs at specific times of the year when allergens such as pollen from trees, grasses, or weeds are prevalent. Treatments for allergic rhinitis include antihistamines, immunotherapy, corticosteroids, decongestants, and other medications. These treatments can be administered through various routes, including oral, nasal, intraocular, and intravenous methods. They are distributed through channels such as retail pharmacies, hospital pharmacies, and online platforms.

The allergic rhinitis drugs market research report is one of a series of new reports that provides allergic rhinitis drugs market statistics, including allergic rhinitis drugs industry global market size, regional shares, competitors with an allergic rhinitis drugs market share, detailed allergic rhinitis drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the allergic rhinitis drugs industry. This allergic rhinitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The allergic rhinitis drugs market consists of sales of mast cell stabilizers, drops, and saline nasal sprays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.